Lilly
1Q Revenues: $5.1 billion (+3%)
1Q Earnings: $4.2 billion (earnings were $1.2 billion 1Q18)
Comments: Key growth products launched since 2014, including Trulicity, Taltz, Verzenio, Basaglar, Olumiant, Jardiance, Cyramza and Emgality represented approximately 39% of revenue. Trulicity sales were $879.7 million in the quarter, up 30%. Taltz sales were up 72% to $252.5 million. Basaglar sales were $251.4 million, up 51%. Verzenio sales were $109.4 million, up from $29.7 million in 1Q18. Alimta sales were flat at $499.2 million, with U.S. revenue up 15% to $281.8 million, and revenue outside the U.S. down 15% to $217.4 million, driven by entry of generic pemetrexed in Germany. Humalog sales were down 8% to $730.8 million, driven by decreased demand. Cialis sales were down 38% to $308.2 million due to generic competition. Earnings reflect the gain on the divestiture of the Elanco Animal Health business.